You are here

Ahmadi, Sara

Positions:

Assistant Professor of Medicine

Medicine, Endocrinology, Metabolism, and Nutrition
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

M.D. 2005

M.D. — Tehran University of Medical Sciences (Iran)

Research Fellow in Nephrology

University of Texas, Medical Branch at Galveston

Internal Medicine Residency

Henry Ford Health System

Clinical Fellowship in Endocrinology

University of Texas, Medical Branch at Galveston

Awards:

Endocrinology Faculty Teaching Award . Fellows in Endocrinology .

Type
Department
Awarded By
Fellows in Endocrinology
Date
June 29, 2017

Publications:

Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines?

The American Thyroid Association recommended thyroid lobectomy as an alternative for low-risk differentiated thyroid cancer. One hypothetical benefit includes avoiding lifelong thyroid hormone supplementation; however, guidelines recommend maintaining the thyroid-stimulating hormone <2 mIU/L postoperatively in low-risk patients. Our hypothesis is that most patients will require hormone supplementation to maintain thyroid-stimulating hormone <2 mIU/L, minimizing this advantage of lobectomy. The goal of this study is to determine how often patients have thyroid-stimulating hormone <2 mIU/L after lobectomy without thyroid hormone supplementation.A retrospective review of 555 consecutive patients who underwent thyroid lobectomy was performed. Thyroid hormone supplementation was documented, along with thyroid-stimulating hormone levels preoperatively, 7 to 10 days, and 2 to 12 months postoperatively.In the study, 478/555 (86%) patients did not take thyroid hormone before thyroidectomy; 394/478 (82%) had thyroid-stimulating hormone levels available at 7 to 10 days postoperatively, and of these, 218 (55%) had thyroid-stimulating hormone >2 mIU/L. From 2 to 12 months postoperatively, of the 225 patients who continued to remain off thyroid hormone supplementation, 132 (59%) experienced a thyroid-stimulating hormone increase to >2 mIU/L; therefore, 350/478 (73%) patients after thyroid lobectomy had thyroid-stimulating hormone levels >2 mIU/L within a year.It is important to counsel patients that to be compliant with the American Thyroid Association guidelines for differentiated thyroid cancer, the majority of patients undergoing thyroid lobectomy may require thyroid hormone supplementation to maintain a thyroid-stimulating hormone level <2 m IU/L.

Authors
Cox, C; Bosley, M; Southerland, LB; Ahmadi, S; Perkins, J; Roman, S; Sosa, JA; Carneiro-Pla, D
MLA Citation
Cox, C, Bosley, M, Southerland, LB, Ahmadi, S, Perkins, J, Roman, S, Sosa, JA, and Carneiro-Pla, D. "Lobectomy for treatment of differentiated thyroid cancer: can patients avoid postoperative thyroid hormone supplementation and be compliant with the American Thyroid Association guidelines?." Surgery 163.1 (January 2018): 75-80.
PMID
29122328
Source
epmc
Published In
Surgery
Volume
163
Issue
1
Publish Date
2018
Start Page
75
End Page
80
DOI
10.1016/j.surg.2017.04.039

VARIABILITY IN THYROID CANCER MANAGEMENT AND PROGNOSIS AMONG HISPANIC VERSUS NON-HISPANIC PATIENTS : 17 YEARS DATA FROM UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AND UNIVERSITY HEALTH SYSTEM AT SAN ANTONIO

Authors
Ahmadi, S; Rojas, CR; Policarpio-Nicolas, ML; Metter, D; Avery, D; Prihoda, TJ; Sabra, MM
MLA Citation
Ahmadi, S, Rojas, CR, Policarpio-Nicolas, ML, Metter, D, Avery, D, Prihoda, TJ, and Sabra, MM. "VARIABILITY IN THYROID CANCER MANAGEMENT AND PROGNOSIS AMONG HISPANIC VERSUS NON-HISPANIC PATIENTS : 17 YEARS DATA FROM UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AND UNIVERSITY HEALTH SYSTEM AT SAN ANTONIO." Endocrine Practice aop (August 17, 2017).
Source
crossref
Published In
Endocrine Practice
Issue
aop
Publish Date
2017
DOI
10.4158/EP171852.OR

Medical management of aggressive differentiated thyroid Cancer

New in the second edition: A section on state-of-the-art, evidence-based management of challenging parathyroid conditions such as multiple endocrine neoplasia and renal hyperparathyroidism A more detailed discussion of thyroid cancer ...

Authors
Ahmadi,Sara, ; Tuttle,Michael,
MLA Citation
Ahmadi,Sara, , Tuttle, andMichael, . "Medical management of aggressive differentiated thyroid Cancer." Thyroid and Parathyroid Diseases Medical and Surgical Management. Thieme, May 25, 2016. (Chapter)
Source
manual
Publish Date
2016

Hürthle cell carcinoma: current perspectives.

Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely invasive tumor. HCC generally has a more aggressive clinical behavior compared with the other differentiated thyroid cancers, and it is associated with a higher rate of distant metastases. Minimally invasive HCC demonstrates much less aggressive behavior; lesions <4 cm can be treated with thyroid lobectomy alone, and without radioactive iodine (RAI). HCC has been observed to be less iodine-avid compared with other differentiated thyroid cancers; however, recent data have demonstrated improved survival with RAI use in patients with HCC >2 cm and those with nodal and distant metastases. Patients with localized iodine-resistant disease who are not candidates for a wait-and-watch approach can be treated with localized therapies. Systemic therapy is reserved for patients with progressive, widely metastatic HCC.

Authors
Ahmadi, S; Stang, M; Jiang, XS; Sosa, JA
MLA Citation
Ahmadi, S, Stang, M, Jiang, XS, and Sosa, JA. "Hürthle cell carcinoma: current perspectives." OncoTargets and therapy 9 (January 2016): 6873-6884. (Review)
Website
http://hdl.handle.net/10161/15141
PMID
27853381
Source
epmc
Published In
OncoTargets and Therapy
Volume
9
Publish Date
2016
Start Page
6873
End Page
6884
DOI
10.2147/ott.s119980

Thyroid Gland

This comprehensive, portable handbook offers an easy-access format that combines electronic content and peer-reviewed videos to provide comprehensive, non-specialty-specific guidance on this ever-evolving technology.

Authors
Ahmadi,Sara, SA; Fish,Stephanie, SF
MLA Citation
Ahmadi,Sara, SA, Fish, andStephanie, SF. "Thyroid Gland." Point of Care Ultrasound Expert Consult - Online and Print. Ed. Soni,Nilam, Arntfield,Robert, and Kory,Pierre. Saunders, August 20, 2014. (Chapter)
Source
manual
Publish Date
2014

Nonclassic congenital adrenal hyperplasia and the heterozygote carrier

Authors
Ahmadi, S; Alvi, S; Urban, RJ
MLA Citation
Ahmadi, S, Alvi, S, and Urban, RJ. "Nonclassic congenital adrenal hyperplasia and the heterozygote carrier." Expert Review of Endocrinology & Metabolism 8.3 (May 2013): 239-246.
Source
crossref
Published In
Expert review of endocrinology & metabolism
Volume
8
Issue
3
Publish Date
2013
Start Page
239
End Page
246
DOI
10.1586/eem.13.18

Pituitary dysfunction after traumatic brain injury: screening and hormone replacement

Authors
Guttikonda, S; Ahmadi, S; Urban, RJ
MLA Citation
Guttikonda, S, Ahmadi, S, and Urban, RJ. "Pituitary dysfunction after traumatic brain injury: screening and hormone replacement." Expert Review of Endocrinology & Metabolism 6.5 (September 2011): 697-703.
Source
crossref
Published In
Expert review of endocrinology & metabolism
Volume
6
Issue
5
Publish Date
2011
Start Page
697
End Page
703
DOI
10.1586/eem.11.59
Show More